

BIOLARGO, INC.  
Form 8-K  
May 29, 2018

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): May 23, 2018

**BioLargo, Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
**of incorporation)**

**000-19709**  
**(Commission File Number)**

**65-0159115**  
**(IRS Employer**  
**Identification No.)**

**14921 Chestnut St., Westminster, California 92683**  
**(Address of principal executive offices) (Zip Code)**

Registrant's telephone number, including area code: (949) 643-9540

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 5.07 Submission of Matters to a Vote of Security Holders**

The Company held its 2018 annual stockholder meeting on May 23, 2018. The following matters were each submitted to a vote of stockholders through the solicitation of proxies or otherwise:

1. A proposal to elect the following seven individuals to our Board of Directors: Dennis P. Calvert, Kenneth R. Code, Dennis E. Marshall, Joseph L. Provenzano, Kent C. Roberts II, John S. Runyan and Jack B. Strommen.
2. Advisory approval of the Company's executive compensation.
3. A proposal to ratify the appointment of Haskell & White LLP as our independent public accounting firm for the 2018 fiscal year.
4. A proposal to increase the authorized capital stock of the Company from 200,000,000 shares of common stock to 400,000,000 shares of common stock.
5. A proposal to adopt the 2018 Equity Incentive Plan.

A quorum was present in person or by proxy. Each matter was approved. The voting results are as follows:

<b>Proposal One</b>	<b>Votes</b>		<b>Broker</b>	<b>Total Votes</b>
	<b>Votes For</b>	<b>Withheld</b>		
				<b>(For + Withheld)</b>
Dennis P. Calvert	34,827,821	640,290	35,954,467	35,468,111
Kenneth R. Code	34,848,821	619,290	35,954,467	35,468,111
Dennis E. Marshall	35,086,896	381,215	35,954,467	35,468,111
Joseph L. Provenzano	34,737,572	730,539	35,954,467	35,468,111
Kent C. Roberts II	35,234,614	233,497	35,954,467	35,468,111
John S. Runyan	35,204,734	263,377	35,954,467	35,468,111
Jack B. Strommen	35,113,776	354,335	35,954,467	35,468,111

  

<b>Proposals 2 - 5</b>	<b>Votes</b>		<b>Broker</b>	<b>Non-</b>	<b>Total votes</b>
	<b>Votes For</b>	<b>Against</b>			
2	34,117,919	1,102,804	247,388	35,954,467	35,468,111

Edgar Filing: BIOLARGO, INC. - Form 8-K

3	69,640,818	357,915	1,423,844	-	71,422,577
4	60,800,613	7,946,285	2,596,033	79,647	71,342,931
5	33,976,146	1,201,591	290,374	35,954,467	35,468,111

For the Advisory Approval of Executive Compensation, prior year votes are as follows:

	<u>Year</u>	<u>Votes For</u>	<u>Votes Against</u>	<u>Votes Abstain</u>	<u>Broker</u>	<u>Non-Vote</u>
	<b>2017</b>	27,248,643	343,971	242,499	28,177,525	
	<b>2016</b>	31,052,733	342,142	240,267	21,119,013	

There were no director nominees other than as set forth above.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:

May  
29,  
2018

BIOLARGO, INC.

By: /s/ Dennis P. Calvert  
Dennis P. Calvert  
President and Chief Executive Officer